title: Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo.
abstract: Clinical intervention studies and experimental studies with lignan-rich diets suggest that lignans may have inhibitory effects on prostate cancer, but no clinical or experimental studies with purified lignans have been published. The purpose of this study was to investigate the effect of a plant lignan 7-hydroxymatairesinol (HMR) on LNCaP human prostate cancer xenografts in athymic mice. Athymic nude male mice were injected subcutaneously with LNCaP cells. Starting 3 days after tumor cell injections, a control diet or a control diet supplemented with 0.15% or 0.30% of HMR was administered to mice and the tumor take rate and growth was observed for 9 weeks. HMR diet inhibited the growth of LNCaP tumors. Mice treated with HMR had smaller tumor volume, lower tumor take rate, increased proportion of nongrowing tumors, and higher tumor cell apoptotic index compared with controls. Furthermore, the cell proliferation index was reduced in mice receiving the 0.30% HMR diet compared with mice receiving the control diet. Our results suggest that dietary HMR started at the early phase of the tumor development inhibits the growth of the LNCaP human prostate cancer xenografts in athymic male mice.
authors.affiliation: University of Turku, Functional Foods Forum, FI-20014 Turku, Finland.
authors.forename: Annika
authors.initials: A
authors.lastname: Bylund
authors.forename: Niina
authors.initials: N
authors.lastname: Saarinen
authors.forename: Jie-Xian
authors.initials: JX
authors.lastname: Zhang
authors.forename: Anders
authors.initials: A
authors.lastname: Bergh
authors.forename: Anders
authors.initials: A
authors.lastname: Widmark
authors.forename: Anders
authors.initials: A
authors.lastname: Johansson
authors.forename: Eva
authors.initials: E
authors.lastname: Lundin
authors.forename: Herman
authors.initials: H
authors.lastname: Adlercreutz
authors.forename: Göran
authors.initials: G
authors.lastname: Hallmans
authors.forename: Pär
authors.initials: P
authors.lastname: Stattin
authors.forename: Sari
authors.initials: S
authors.lastname: Mäkela
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002277:Carcinoma / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D004032:Diet; D004195:Disease Models, Animal; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology; D017705:Lignans / Q000737:chemistry / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D009368:Neoplasm Transplantation; D048789:Phytoestrogens / Q000378:metabolism / Q000652:urine; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D016588:Anticarcinogenic Agents; D007529:Isoflavones; D017705:Lignans; D048789:Phytoestrogens; C419306:hydroxymatairesinol; D017430:Prostate-Specific Antigen